All patients were receiving optimized HF therapy (according to current guidelines at the time of enrollment) including ACE inhibitors/angiotensin receptor blockers (91%), mineralcorticoid receptor antagonist (75%), betablockers (78%). The gene discussed is ACE; the disease is hydrops fetalis.